Dysfunction of the recurrent laryngeal nerve and the potential of gene therapy

Annals of Otology, Rhinology and Laryngology

Volumn 116, Issue 6, 2007, Pages 441-448

  Heavner, S Brett ^a   Rubin, Adam D ^b   Fung, Kevin ^c   Old, Matthew ^a   Hogikyan, Norman D ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Lakeshore Voice Center   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Crush injury; Gene therapy; Laryngeal paralysis; Nerve injury; Nerve regeneration; Neurotrophic factor; Recurrent laryngeal nerve; Vocal fold paralysis

Indexed keywords

NEUROTROPHIC FACTOR; VIRUS VECTOR;

AMBIGUUS NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; DEGENERATIVE DISEASE; DISEASE SEVERITY; DYSPHAGIA; GENE THERAPY; NERVE FUNCTION; NERVE INJURY; NERVE REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; RECURRENT LARYNGEAL NERVE PALSY; VOICE;

EID: 34250870051     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940711600609     Document Type: Article

References (67)

1. Dursun G, Sataloff RT, Spiegel JR, Mandel S, Heuer RJ, Rosen DC. Superior laryngeal nerve paresis and paralysis. J Voice 1996;10:206-11.
2. Hogikyan ND, Johns MM, Kileny PR, Urbanchek M, Carroll WR, Kuzon WM Jr. Motion-specific laryngeal reinnervation using muscle-nerve-muscle neurotization. Ann Otol Rhinol Laryngol 2001;110:801-10.
3. Rubin A, Moblev B, Hogikyan N, et al. Delivery of an adenoviral vector to the crushed recurrent laryngeal nerve. Laryngoscope 2003;113:985-9.
4. Myssiorek D. Recurrent laryngeal nerve paralysis: anatomy and etiology. Otolaryngol Clin North Am 2004;37:25-44.
5. Lai SY, Mandel SJ, Weber RS. Management of thyroid neoplasms: surgical anatomy and embryology. In: Cummings CW, Haughey BH, Thomas JR, et al. eds. Cummings otolaryngology-head and neck surgery. 4th ed. St Louis, Mo: Mosby. 2005:2687-723.
6. Hollinshead WH. Anatomy for surgeons: the head and neck. 3rd ed. Philadelphia, Pa: Harper & Row, 1982.
7. Rubin A, Sataloff R. Vocal fold paresis and paralysis. In: Sataloff R. Professional voice: the science and art of clinical care. 3rd ed. San Diego. Calif: Plural Publishing, 2005:871-86.
8. Horn KL, Crumley RL. The physiology of nerve injury and repair. Otolaryngol Clin North Am 1984;77:321-33.
9. Bridge PM, Ball DJ, Mackinnon SE, et al. Nerve crush injuries - a model for axonotmesis. Exp Neurol 1994;127:284-90.
10. Shindo ML, Herzon GD, Hanson DG, Cain DJ, Sahgal V. Effects of denervation on laryngeal muscles: a canine model. Laryngoscope 1992;102:663-9.
11. Crumley RL. Laryngeal synkinesis: its significance to the laryngologist. Ann Otol Rhinol Laryngol 1989;98:87-92.
12. Crumley RL. Laryngeal synkinesis revisited. Ann Otol Rhinol Laryngol 2000;109:365-71.
13. Zeitels SM, Casiano RR, Gardner GM, Hogikyan ND, Koufman JA, Rosen CA: Voice and Swallowing Committee. American Academy of Otolaryngology-Head and Neck Surgery. Management of common voice problems: Committee report. Otolaryngol Head Neck Surg 2002;126:333-48.
14. Ramig LO, Scherer RC. Speech therapy for neurologic disorders of the larynx. In: Blitzer A, Brin ME, Sasaki CT, Fahn S, Harris KS, eds. Neurologic disorders of the larynx. New York, NY: Thieme Medical Publishers, 1992:163-81.
15. Heuer RJ, Sataloff RT, Emerich K, et al. Unilateral recurrent laryngeal nerve paralysis: the importance of "preoperative" voice therapy. J Voice 1997;11:88-94.
16. Kelchner LN, Stemple JC, Gerdeman E, Le Borgne W, Adam S. Etiology, pathophysiology, treatment choices, and voice results for unilateral adductor vocal fold paralysis: a 3-year retrospective. J Voice 1999;13:592-601.
17. Zeitels SM. New procedures for paralytic dysphonia: adduction arytenopexy. Goretex medialization laryngoplasty, and cricothyroid subluxation. Otolaryngol Clin North Am 2000;33: 841-54.
18. Zeitels SM, Hillman RE, Desloge RB, Bunting GA. Cricothyroid subluxation: a new innovation for enhancing the voice with laryngoplastic phonosurgery. Ann Otol Rhinol Laryngol 1999;108:1126-31.
19. Zeitels SM, Hochman I, Hillman RE. Adduction arytenopexy: a new procedure for paralytic dysphonia with implications for implant medializalion. Ann Otol Rhinol Laryngol Suppl 1998;107(suppl 173).
20. Baldissera F, Tredici G, Marini G, et al. Innervation of the paralyzed laryngeal muscles by phrenic motoneurons. A quantitative study by light and electron microscopy. Laryngoscope 1992;102:907-16.
21. Jacobs IN, Sanders I, Wu BL, Biller HF. Reinnervation of the canine posterior cricoarytenoid muscle with sympathetic preganglionic neurons. Ann Otol Rhinol Laryngol 1990;99:167-74.
22. Paniello RC, West SE, Lee P. Laryngeal reinnervation with the hypoglossal nerve. I. Physiology, histochemistry, electromyography, and retrograde labeling in a canine model. Ann Otol Rhinol Laryngol 2001;110:532-42.
23. Tucker HM. Long-term results of nerve-muscle pedicle reinnervation for laryngeal paralysis. Ann Otol Rhinol Laryngol 1989;98:674-6.
24. Sercarz JA, Nguyen L, Nasri S, Graves MC, Wenokur R, Berke GS. Physiologic motion after laryngeal nerve reinnervation: a new method. Otolaryngol Head Neck Surg 1997;116:466-74.
25. Flint PW, Downs DH, Coltrera MD. Laryngeal synkinesis following reinnervation in the rat. Neuroanatomic and physiologic study using retrograde fluorescent tracers and electromyography. Ann Otol Rhinol Laryngol 1991;100:797-806.
26. Chhetri DK, Gerratt BR, Kreiman J, Berke GS. Combined arytenoid adduction and laryngeal reinnervation in the treatment of vocal fold paralysis. Laryngoscope 1999;109:1928-36.
27. Bronialowski M, Tucker HM, Nose Y. The future of electronic pacing in laryngeal rehabilitation. Am J Otolaryngol 1990;11:51-62.
28. Bergmann K, Warzel H, Eckhardt HU, Hopstock U, Hermann V, Gerhardt HJ. Long-term implantation of a system of electrical stimulation of paralyzed laryngeal muscles in dogs. Laryngoscope 1988;98:455-9.
29. Kano S, Sasaki CT. Pacing parameters of the canine posterior cricoarytenoid muscle. Ann Otol Rhinol Laryngol 1991; 100:584-8.
30. Lindholm D, Carroll P, Tzimagiogis G, Thoenen H. Autocrine-paracrine regulation of hippocampal neuron survival by IGF-1 and the neurotrophins BDNF, NT-3 and NT-4. Eur J Neurosci 1996;8:1452-60.
31. Russell JW, Windebank AJ, Schenone A, Feldman EL. Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. J Neurobiol 1998;36:455-67.
32. Saito K, Shiotani A, Watabe K, Moro K, Fukuda H, Ogawa K. Adenoviral GDNF gene transfer prevents motoneuron loss in the nucleus ambiguus. Brain Res 2003;962:61-7.
33. Jin G, Omori N, Li F, et al. Protection against ischemic brain damage by GDNF affecting cell survival and death signals. Neurol Res 2003;25:249-53.
34. Bondy CA, Cheng CM. Signaling by insulin-like growth factor I in brain. Eur J Pharmacol 2004;490:25-31.
35. Rabinovsky ED. The multifunctional role of IGF-1 in peripheral nerve regeneration. Neurol Res 2004;26:204-10.
36. Lewin GR. Neurotrophic factors and pain. Semin Neurosci 1995;7:227-32.
37. Dittrich F, Thoenen H, Sendtner M. Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann Neurol 1994;35:151-63.
38. Kang UJ. Genetic modification of cells with retrovirus vectors for grafting into the central nervous system. In: Kaplitt MG, Loewy AD, eds. Viral vectors: gene therapy and neuroscience applications. San Diego. Calif: Academic Press, 1995:211-37.
39. Nakahara Y, Gage FH, Tuszynski MH. Grafts of fibroblasts genetically modified to secrete NGF, BDNF, NT-3, or basic FGF elicit differential responses in the adult spinal cord. Cell Transplant 1996;5:191-204.
40. Tuszynski MH, Murai K, Blesch A, Grill R, Miller I. Functional characterization of NGF-secreting cell grafts to the acutely injured spinal cord. Cell Transplant 1997;6:361-8.
41. Boulis NM, Bhatia V, Brindle TI, et al. Adenoviral nerve growth factor and β-galactosidase transfer to spinal cord: a behavioral and histological analysis. J Neurosurgery 1998;90(suppl):99-108.
42. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993; 3:219-23.
43. Boulis NM, Turner DE, Dice JA, Bhatia V, Feldman EL. Characterization of adenoviral gene expression in spinal cord after remote vector delivery. Neurosurgery 1999;45:131-8.
44. Rubin AD, Hogikyan ND, Sullivan K, Boulis N, Feldman EL. Remote delivery of rAAV-GFP to the rat brainstem through the recurrent laryngeal nerve. Laryngoscope 2001;111:2041-5.
45. Neve RL. Adenovirus vectors enter the brain. Trends Neurosci 1993;16:251-3.
46. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993;3:499-503.
47. Wickham TJ. Targeting adenovirus. Gene Ther 2000;7: 110-4.
48. Liu Y, Himes BT, Moul J, et al. Application of recombinant adenovirus for in vivo gene delivery to spinal cord. Brain Res 1997;768:19-29.
49. Davidson BL, Doran SE, Shewach DS, Latta JM, Hartman JW, Roessler BJ. Expression of Escherichia coli β-galactosidase and rat HPRT in the CNS of Macaca mulatta following adenoviral mediated gene transfer. Exp Neurol 1994;125:258-67.
50. Peel AL, Klein RL. Adeno-associated virus vectors: activity and applications in the CNS. J Neurosci Methods 2000; 98:95-104.
51. Peel AL, Zolotukhin S, Schrimsher GW, Muzyczka N, Reier PJ. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther 1997;4:16-24.
52. Tuszynski MH. U HS. Alksne J, et al. Growth factor gene therapy for Alzheimer disease. Neurosurg Focus 2002;13:e5.
53. Brizard M, Carcenac C, Bemelnians AP, Feuerstein C, Mallet J, Savasta M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol Dis 2006;21:90-101.
54. Dowd E, Monville C, Torres EM, et al. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur J Neurosci 2005;22:2587-95.
55. McBride JL, Ramaswamy S, Gasmi M, et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2006;103:9345-50.
56. Hottinger AF, Azzouz M, Deglon N, Aebischer P, Zurn AD. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 2000;20:5587-93.
57. Araki K, Shiotani A, Watabe K, Saito K, Moro K, Ogawa K. Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury. Gene Ther 2006;13:296-303.
58. Tsai TH, Chen SL, Xiao X, Chiang YH, Tsao YP. Gene-therapy of focal cerebral ischemia using defective recombinant adeno-associated virus vectors. Front Biosci 2006;11:2061-70.
59. Sugiura S, Kitagawa K, Tanaka S, et al. Adenovirus-mediated gene transfer of heparin-binding epidermal growth factor-like growth factor enhances neurogenesis and angiogenesis after focal cerebral ischemia in rats. Stroke 2005;36:859-64.
60. Schuettauf F, Vorwerk C, Naskar R, et al. Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity. Curr Eye Res 2004;29:379-86.
61. Taylor L, Jones L, Tuszynski MH, Blesch A. Neurotrophin-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord. J Neurosci 2006;26:9713-21.
62. Chattopadhyay M, Wolfe D, Mata M, Huang S, Glorioso JC, Fink DJ. Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. Mol Ther 2005;12:307-13.
63. Romero MI, Smith GM. Adenoviral gene transfer into the normal and injured spinal cord: enhanced transgene stability by combined administration of temperature-sensitive virus and transient immune blockade. Gene Ther 1998;5:1612-21.
64. Turner DE, Noordmans AJ, Feldman EL, Boulis NM. Remote adenoviral gene delivery to the spinal cord: contralateral delivery and reinjection. Neurosurgery 2001;48:1309-17.
65. Shiotani A, O'Malley BW Jr, Coleman ME, Flint PW. Human insulinlike growth factor 1 gene transfer into paralyzed rat larynx: single vs multiple injection. Arch Otolaryngol Head Neck Surg 1999;125:555-60.
66. Nakagawa H, Shiotani A, O'Malley BW Jr, Coleman ME, Flint PW. Timing of human insulin-like growth factor-1 gene transfer in reinnervating laryngeal muscle. Laryngoscope 2004;114:726-32.
67. Moro K, Shiotani A, Watabe K, et al. Adenoviral gene transfer of BDNF and GDNF synergistically prevent motoneuron loss in the nucleus ambiguus. Brain Res 2006;1076:1-8.